Pharvaris
PHVS
31.68
+0.56
+1.80%
Pharvaris
US · PHVS
#2729 by market cap
Listed 2021
31.68
+0.56
+1.80%
Live - 5344 symbols - heartbeat 236s ago
· 2026-10-07 19:54
After-hours
31.68
0.00%
- Market cap
- 2.22B
- P/E (TTM)i
- -10.88
- P/Bi
- 6.60
- EPSi
- -3.33
- Div yieldi
- 0.00%
- 52W posi
- 49%
Reader sentiment
Are you bullish or bearish on PHVS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 97.45% -0.16pp
- Institutions
- 142 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund44.81%
Hedge Fund29.89%
Mutual Fund21.44%
Individual/Insider2.11%
Public Company0.64%
Private Company0.55%
Other0.44%
Top holders as of 2026-06-30
FMR
9.35% · 6.57M sh
General Atlantic Service Company, L.P.
9.33% · 6.55M sh
Foresite Capital Management, LLC
7.75% · 5.44M sh
venBio LLC
6.61% · 4.64M sh
Viking Global Investors LP
5.20% · 3.65M sh
EQT Life Sciences
5.07% · 3.56M sh
Eqt Fund Management S.à R.L.
4.88% · 3.42M sh
Deerfield Management Company, L.P.
4.81% · 3.38M sh
Bain Capital Life Sciences Investors, LLC
3.81% · 2.68M sh
Wellington Management Group
3.41% · 2.39M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 1 buys · 49 sells
| Name | Role | Stake |
|---|---|---|
| Berndt Axel Modig | Chief Executive Officer | 1.11% |
| Hans J. G. C. Schikan | Independent Vice Chairperson | 0.16% |
| David Nassif | Chief Financial Officer | 0.16% |
| Anne Lesage | Chief Early Development Officer | 0.14% |
| Annick Deschoolmeester | Chief Human Resources Officer | 0.13% |
| Peng Lu | Chief Medical Officer | 0.10% |
| David Meeker | Independent Non-Executive Chairperson | 0.09% |
| Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer | 0.07% |
| Stefan Abele | Chief Technology Operations Officer | 0.06% |
| Wim Souverijns | Chief Community Engagement & Commercial Officer | 0.06% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-22 | Viviane Monges | Non-Executive Director | Derivative Exercise and Sale | -11,969 | $8.05–33.05 |
| 2026-09-21 | Hans J. G. C. Schikan | Independent Vice Chairperson | Derivative Exercise and Sale | -800 | $20.00–36.19 |
| 2026-09-21 | Peng Lu | Chief Medical Officer | Derivative Exercise and Retained | +45,308 | $2.59 |
| 2026-09-20 | David Nassif | Chief Financial Officer | Other Disposition | -500 | -- |
| 2026-09-20 | David Nassif | Chief Financial Officer | Open Market Disposition | -6,000 | $36.47 |
| 2026-09-16 | Robert Glassman | Independent Non-Executive Director | Derivative Exercise and Sale | -14,493 | $18.14–38.56 |
| 2026-09-16 | Berndt Axel Modig | Chief Executive Officer | Other Disposition | -300,000 | $35.00 |
| 2026-09-16 | Hans J. G. C. Schikan | Independent Vice Chairperson | Private Disposition | -200,000 | $35.00 |
| 2026-09-16 | Elisabeth Bjork | Non-Executive Director | Derivative Exercise and Sale | -52,500 | $14.39–37.89 |
| 2026-09-16 | Anne Lesage | Chief Early Development Officer | Open Market Disposition | -20,000 | $38.27 |
| 2026-09-16 | Peng Lu | Chief Medical Officer | Derivative Exercise and Sale | -100,000 | $2.59–35.00 |
| 2026-09-14 | Robert Glassman | Independent Non-Executive Director | Derivative Exercise and Sale | -8,667 | $22.31–38.27 |
| 2026-09-14 | Wim Souverijns | Chief Community Engagement & Commercial Officer | Automatic Disposition | -6,090 | $38.99 |
| 2026-09-14 | Stefan Abele | Chief Technology Operations Officer | Open Market Disposition | -1,400 | $39.24 |
| 2026-09-14 | Stefan Abele | Chief Technology Operations Officer | Derivative Exercise and Sale | -45,000 | $16.40–38.14 |
| 2026-09-13 | Berndt Axel Modig | Chief Executive Officer | Automatic Disposition | -2,291 | $39.40 |
| 2026-09-13 | Wim Souverijns | Chief Community Engagement & Commercial Officer | Derivative Exercise and Sale | -20,000 | $17.43–39.31 |
| 2026-09-13 | Peng Lu | Chief Medical Officer | Sale to Issuer | -226 | $37.51–38.02 |
| 2026-09-10 | Peng Lu | Chief Medical Officer | Derivative Exercise and Sale | -15,000 | $2.59–40.13 |
| 2026-09-09 | Anne Lesage | Chief Early Development Officer | Derivative Exercise and Sale | -30,000 | $8.05–38.30 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.